AVITA Medical annual r&d spending
2018
2019
2020
2021
2021
2022
2023
2024
2025
AVITA Medical R&D Spending Growth & History (RCEL)
AVITA Medical's r&d spending was $20.8M for fiscal 2025.
View full AVITA Medical company overviewAVITA Medical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.8M | $479,000 | +2.35% |
| 2024 | 2024-12-31 | $20.4M | −$461,000 | −2.21% |
| 2023 | 2023-12-31 | $20.8M | $7.0M | +50.26% |
| 2022 | 2022-12-31 | $13.9M | $6.3M | +82.67% |
| 2021 · Dec 31 | 2021-12-31 | $7.6M | — | — |
| 2021 · Jun 30 | 2021-06-30 | $14.8M | $5.7M | +61.70% |
| 2020 | 2020-06-30 | $9.2M | $1.2M | +14.49% |
| 2019 | 2019-06-30 | $8.0M | $1.7M | +27.92% |
| 2018 | 2018-06-30 | $6.3M | — | — |
AVITA Medical quarterly r&d spending
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.1M | −$39,000 | −0.76% |
| Q1 2026 | 2026-03-31 | $5.6M | −$655,000 | −10.42% |
| Q4 2025 | 2025-12-31 | $5.7M | $839,000 | +17.30% |
| Q3 2025 | 2025-09-30 | $3.7M | −$1.7M | −30.95% |
| Q2 2025 | 2025-06-30 | $5.1M | $230,000 | +4.71% |
| Q1 2025 | 2025-03-31 | $6.3M | $1.1M | +20.99% |
| Q4 2024 | 2024-12-31 | $4.9M | −$1.9M | −28.29% |
| Q3 2024 | 2024-09-30 | $5.4M | $1.0M | +23.53% |
| Q2 2024 | 2024-06-30 | $4.9M | −$189,000 | −3.72% |
| Q1 2024 | 2024-03-31 | $5.2M | $608,000 | +13.26% |
| Q4 2023 | 2023-12-31 | $6.8M | $3.4M | +100.21% |
| Q3 2023 | 2023-09-30 | $4.4M | $595,000 | +15.66% |
| Q2 2023 | 2023-06-30 | $5.1M | $2.0M | +65.94% |
| Q1 2023 | 2023-03-31 | $4.6M | $966,000 | +26.69% |
| Q4 2022 | 2022-12-31 | $3.4M | — | — |
| Q3 2022 | 2022-09-30 | $3.8M | $411,000 | +12.13% |
| Q2 2022 | 2022-06-30 | $3.1M | −$915,000 | −23.02% |
| Q1 2022 · Mar 31 | 2022-03-31 | $3.6M | −$489,000 | −11.90% |
| Q1 2022 · Sep 30 | 2021-09-30 | $3.4M | $14,000 | +0.41% |
| Q4 2021 | 2021-06-30 | $4.0M | $1.4M | +56.58% |
| Q3 2021 | 2021-03-31 | $4.1M | $1.6M | +64.69% |
| Q2 2021 | 2020-12-31 | $3.4M | $1.0M | +45.37% |
| Q1 2021 | 2020-09-30 | $3.4M | $1.6M | +85.49% |
| Q4 2020 | 2020-06-30 | $2.5M | $466,000 | +22.49% |
| Q3 2020 | 2020-03-31 | $2.5M | $686,000 | +37.92% |
| Q2 2020 | 2019-12-31 | $2.3M | $293,000 | +14.51% |
| Q1 2020 | 2019-09-30 | $1.8M | −$153,000 | −7.76% |
| Q4 2019 | 2019-06-30 | $2.1M | — | — |
| Q3 2019 | 2019-03-31 | $1.8M | — | — |
| Q2 2019 | 2018-12-31 | $2.0M | — | — |
| Q1 2019 | 2018-09-30 | $2.0M | — | — |
AVITA Medical r&d spending trends
Between the periods ended 2018-06-30 and 2025-12-31, AVITA Medical's r&d spending increased from $6.3M to $20.8M, a change of $14.6M. The latest reported quarter, Q2 2026, shows $5.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AVITA Medical source filings ↗